Results 141 to 150 of about 239,343 (311)

Lipid‐Based Nanoparticles in Cancer Therapy: Advances in Targeted Drug Delivery and Therapeutic Potential for Renal Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
This review explores the transformative potential of lipid‐based nanoparticles (LNPs) in renal cell carcinoma (RCC) therapy. It systematically analyzes six LNP platforms‐from liposomes to hybrid nanoparticles‐highlighting their unique advantages in targeted drug delivery, resistance reversal, and immunomodulation.
Wei Yao   +7 more
wiley   +1 more source

Research impact analysis of international funding agencies in the realm of allergy and immunology. [PDF]

open access: yesAllergy, 2022
Adachi T   +22 more
europepmc   +1 more source

Repositioning Antimicrobial Peptides Against WHO‐Priority Fungi

open access: yesAdvanced Science, EarlyView.
The growing burden of drug‐resistant fungal infections, driven by pathogens such as Candida auris, Cryptococcus neoformans, and Aspergillus fumigatus, underscores the urgent need for novel antifungal therapies. This review explores antimicrobial peptides as promising agents with membrane‐disruptive activity, immunomodulatory properties, and delivery ...
Cesar Augusto Roque‐Borda   +12 more
wiley   +1 more source

Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology [PDF]

open access: bronze, 2006
Jordan S. Orange   +9 more
openalex   +1 more source

Harnessing the Biological Responses Induced by Nanomaterials for Enhanced Cancer Therapy

open access: yesAggregate, EarlyView.
Nanomaterial (NM)‐induced toxicity can be strategically repurposed for cancer therapy. This review summarizes the mechanism by which NMs selectively activate specific cellular processes to regulate cell fate independently. We also discussed how NMs‐induced biological responses can be leveraged as therapeutic strategies for cancer treatment.
Liting Wang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy